Crohn's Disease clinical trials
Showing 101–136 of 136 active trials. Describe your situation to see which ones you may be eligible for.
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Regulation of Mucosal Healing in Inflammatory Bowel Disease
- Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance
- A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease
- Online Pain Education for Crohn's Disease and Ulcerative Colitis
- Tailored Anti-Inflammatory American Diet for Patients With Crohn's Disease
- Ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Crohn's Disease
- Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis
- Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease
- Oral N-acetylglucosamine in Crohn's Disease
- Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
- VR Therapies for IBD
- Xylitol Use for Decolonization of C. Difficile in Patients With IBD
- Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease
- NaviCam Patency Capsule to Verify Gastrointestinal Patency
- Impact of a Human Origin Heat Inactivated Probiotic-Lactobacillus Paracasei D3.5 (LpD3.5) as Dietary Supplement on Gut Mucin and Intestinal Permeability in Adults With IBD
- Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease
- A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
- Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
- Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis
- The EDICT Trial - Therapy for Inflammatory Bowel Disease Flares
- Digital Mind Body Intervention Among Black and Hispanic Patients Living With Inflammatory Bowel Disease
- Mayo Clinic IBD Biobank
- CorEvitas Inflammatory Bowel Disease (IBD) Registry
- Improving the Quality of Care for Adults With Inflammatory Bowel Disease
- Fecal Microbiome Transplant
- Gene Expression in Inflammatory Bowel Disease
- Thermal Measurements of the Gut With a Colonoscope Compatible Thermal Probe
- Utility of Random Biopsies in Patients With Inflammatory Bowel Disease
- Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
- Enabling Microbiomics- Driven Personalized Nutrition
- Quest to Analyze One Thousand Humans Meditating
- RISE: A Remote Study of Insomnia Treatment in Crohn's Disease
- Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
- Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.